The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
APOBEC3F Can Inhibit the Accumulation of HIV-1 Reverse Transcription Products in the Absence of Hypermutation
Open accessAbstract
APOBEC3F (apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1-like protein 3F) is a cytidine deaminase that, like APOBEC3G, is able to restrict the replication of HIV-1/delta vif. Initial studies revealed high numbers of mutations in the cDNA of viruses produced in the presence of these proteins, suggesting that cytidine deamination underpinned the inhibition of infection. However, we have recently shown that catalytically inactive APOBEC3G proteins, derived through mutation of the C-terminal cytidine deaminase motif, still exert a substantial antiviral effect. Here, we have generated a panel of APOBEC3F mutant proteins and show that the C-terminal cytidine deaminase motif is essential for catalytic activity and that catalytic activity is not necessary for the antiviral effect of APOBEC3F. Furthermore, we demonstrate that the antiviral activities of wild-type and catalytically inactive APOBEC3F and APOBEC3G proteins correspond well with reductions in the accumulation of viral reverse transcription products. Additional comparisons between APOBEC3F and APOBEC3G suggest that the loss of deaminase activity is more detrimental to APOBEC3G function than to APOBEC3F function, as reflected by perturbations to the suppression of reverse transcript accumulation as well as antiviral activity. Taken together, these data suggest that both APOBEC3F and APOBEC3G are able to function as antiviral factors in the absence of cytidine deamination, that this editing-independent activity is an important aspect of APOBEC protein-mediated antiviral phenotypes, but that APOBEC3F may be a better model in which to study it.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells
Chiu, Y.-L., Soros, V. B., Kreisberg, J. F., Stopak, K., Yonemoto, W., & Greene, W. C. (2005) · Nature · doi:10.1038/nature03493 · Cited by 439
RetractedIsolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
Sheehy, A. M., Gaddis, N. C., Choi, J. D., & Malim, M. H. (2002) · Nature · doi:10.1038/nature00939 · Cited by 2,327
Self-citationWei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., & Trono, D. (2003) · Nature · doi:10.1038/nature01709 · Cited by 1,486
DNA Deamination Mediates Innate Immunity to Retroviral Infection
Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., & Malim, M. H. (2003) · Cell · doi:10.1016/s0092-8674(03)00423-9 · Cited by 1,266
Self-citationInduction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex
Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., & Yu, X.-F. (2003) · Science · doi:10.1126/science.1089591 · Cited by 1,200
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., & Gao, L. (2003) · Nature · doi:10.1038/nature01707 · Cited by 1,059
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
Sheehy, A. M., Gaddis, N. C., & Malim, M. H. (2003) · Nature Medicine · doi:10.1038/nm945 · Cited by 967
Self-citationSpecies-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif
Mariani, R., Chen, D., Schröfelbauer, B., Navarro, F., König, R., Bollman, B., Münk, C., Nymark-McMahon, H., & Landau, N. R. (2003) · Cell · doi:10.1016/s0092-8674(03)00515-4 · Cited by 903
The Protein Network of HIV Budding
von Schwedler, U. K., Stuchell, M., Müller, B., Ward, D. M., Chung, H.-Y., Morita, E., Wang, H. E., Davis, T., He, G.-P., Cimbora, D. M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00714-1 · Cited by 815
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
Marin, M., Rose, K. M., Kozak, S. L., & Kabat, D. (2003) · Nature Medicine · doi:10.1038/nm946 · Cited by 798
Stopak, K., de Noronha, C., Yonemoto, W., & Greene, W. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00353-8 · Cited by 732
An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22
Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., & Navaratnam, N. (2002) · Genomics · doi:10.1006/geno.2002.6718 · Cited by 708
Hypermutation of HIV-1 DNA in the Absence of the Vif Protein
Lecossier, D., Bouchonnet, F., Clavel, F., & Hance, A. J. (2003) · Science · doi:10.1126/science.1083338 · Cited by 651
Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins
Bishop, K. N., Holmes, R. K., Sheehy, A. M., Davidson, N. O., Cho, S.-J., & Malim, M. H. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.057 · Cited by 619
Self-citationRNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators
Harris, R. S., Petersen-Mahrt, S. K., & Neuberger, M. S. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00742-6 · Cited by 603
Kim, S. Y., Byrn, R., Groopman, J., & Baltimore, D. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3708-3713.1989 · Cited by 577
Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity
Newman, E. N. C., Holmes, R. K., Craig, H. M., Klein, K. C., Lingappa, J. R., Malim, M. H., & Sheehy, A. M. (2005) · Current Biology · doi:10.1016/j.cub.2004.12.068 · Cited by 480
Self-citationMehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., & Gabuzda, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313093200 · Cited by 474
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV‐1 and HIV‐2 Vif proteins
Wiegand, H. L., Doehle, B. P., Bogerd, H. P., & Cullen, B. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600246 · Cited by 470
The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G
Conticello, S. G., Harris, R. S., & Neuberger, M. S. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.034 · Cited by 469
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells
von Schwedler, U., Song, J., Aiken, C., & Trono, D. (1993) · Journal of Virology · doi:10.1128/jvi.67.8.4945-4955.1993 · Cited by 444
APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo
Liddament, M. T., Brown, W. L., Schumacher, A. J., & Harris, R. S. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.050 · Cited by 440
Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication
Zheng, Y.-H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., & Peterlin, B. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.6073-6076.2004 · Cited by 435
Inhibition of Hepatitis B Virus Replication by APOBEC3G
Turelli, P., Mangeat, B., Jost, S., Vianin, S., & Trono, D. (2004) · Science · doi:10.1126/science.1092066 · Cited by 433
APOBEC3A Is a Potent Inhibitor of Adeno-Associated Virus and Retrotransposons
Chen, H., Lilley, C. E., Yu, Q., Lee, D. V., Chou, J., Narvaiza, I., Landau, N. R., & Weitzman, M. D. (2006) · Current Biology · doi:10.1016/j.cub.2006.01.031 · Cited by 389
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition
Bogerd, H. P., Wiegand, H. L., Hulme, A. E., Garcia-Perez, J. L., O’Shea, K. S., Moran, J. V., & Cullen, B. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603313103 · Cited by 375
Cytidine Deaminase. The 2·3 Å Crystal Structure of an Enzyme: Transition-state Analog Complex
Betts, L., Xiang, S., Short, S. A., Wolfenden, R. V., & Carter, C. W. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1018 · Cited by 374
APOBEC3 Proteins Inhibit Human LINE-1 Retrotransposition
Muckenfuss, H., Hamdorf, M., Held, U., Perković, M., Löwer, J., Cichutek, K., Flory, E., Schumann, G. G., & Münk, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601716200 · Cited by 356
Beale, R. C. L., Petersen-Mahrt, S. K., Watt, I. N., Harris, R. S., Rada, C., & Neuberger, M. S. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.046 · Cited by 339
Fouchier, R. A. M. (1997) · The EMBO Journal · doi:10.1093/emboj/16.15.4531 · Cited by 339
Complementary function of the two catalytic domains of APOBEC3G
Navarro, F., Bollman, B., Chen, H., König, R., Yu, Q., Chiles, K., & Landau, N. R. (2005) · Virology · doi:10.1016/j.virol.2005.01.011 · Cited by 305
Suspène, R., Guétard, D., Henry, M., Sommer, P., Wain-Hobson, S., & Vartanian, J.-P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408223102 · Cited by 304
APOBEC3B and APOBEC3C Are Potent Inhibitors of Simian Immunodeficiency Virus Replication
Yu, Q., Chen, D., König, R., Mariani, R., Unutmaz, D., & Landau, N. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408802200 · Cited by 293
Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination
Bishop, K. N., Holmes, R. K., & Malim, M. H. (2006) · Journal of Virology · doi:10.1128/jvi.00839-06 · Cited by 293
Self-citationRole and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors
Cullen, B. R. (2006) · Journal of Virology · doi:10.1128/jvi.80.3.1067-1076.2006 · Cited by 284
APOBEC3B and APOBEC3F Inhibit L1 Retrotransposition by a DNA Deamination-independent Mechanism
Stenglein, M. D., & Harris, R. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602367200 · Cited by 277
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells
Bogerd, H. P. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj416 · Cited by 273
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition
Chiu, Y.-L., Witkowska, H. E., Hall, S. C., Santiago, M., Soros, V. B., Esnault, C., Heidmann, T., & Greene, W. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604524103 · Cited by 244
Human Immunodeficiency Virus cDNA Metabolism: Notable Stability of Two-Long Terminal Repeat Circles
Butler, S. L., Johnson, E. P., & Bushman, F. D. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.3739-3747.2002 · Cited by 238
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif
Doehle, B. P., Schäfer, A., & Cullen, B. R. (2005) · Virology · doi:10.1016/j.virol.2005.06.005 · Cited by 229
Haché, G., Liddament, M. T., & Harris, R. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500382200 · Cited by 189
Simon, J. H., & Malim, M. H. (1996) · Journal of Virology · doi:10.1128/jvi.70.8.5297-5305.1996 · Cited by 188
Self-citationSova, P., & Volsky, D. J. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.6322-6326.1993 · Cited by 180
Janini, M., Rogers, M., Birx, D. R., & McCutchan, F. E. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.7973-7986.2001 · Cited by 175
Kieffer, T. L., Kwon, P., Nettles, R. E., Han, Y., Ray, S. C., & Siliciano, R. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1975-1980.2005 · Cited by 172
G to A hypermutation of hepatitis B virus†
Noguchi, C., Ishino, H., Tsuge, M., Fujimoto, Y., Imamura, M., Takahashi, S., & Chayama, K. (2005) · Hepatology · doi:10.1002/hep.20580 · Cited by 153
Liu, B., Sarkis, P. T. N., Luo, K., Yu, Y., & Yu, X.-F. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9579-9587.2005 · Cited by 151
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells
Simon, J. H., Fouchier, R. A. M., Southerling, T. E., Guerra, C. B., Grant, C. K., & Malim, M. H. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5259-5267.1997 · Cited by 148
Self-citationKaiser, S. M., & Emerman, M. (2005) · Journal of Virology · doi:10.1128/jvi.80.2.875-882.2006 · Cited by 141
Vartanian, J., Meyerhans, A., Sala, M., & Wain–Hobson, S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3092 · Cited by 138
APOBEC‐mediated interference with hepadnavirus production†
Rösler, C., Köck, J., Kann, M., Malim, M. H., Blum, H. E., Baumert, T. F., & von Weizsäcker, F. (2005) · Hepatology · doi:10.1002/hep.20801 · Cited by 135
Self-citationMacGinnitie, A. J., Anant, S., & Davidson, N. O. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14768 · Cited by 130
Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates
Zennou, V., & Bieniasz, P. D. (2006) · Virology · doi:10.1016/j.virol.2005.12.035 · Cited by 107
Priet, S., Gros, N., Navarro, J., Boretto, J., Canard, B., Quérat, G., & Sire, J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.01.016 · Cited by 96
Harris, R. S., Sheehy, A. M., Craig, H. M., Malim, M. H., & Neuberger, M. S. (2003) · Nature Immunology · doi:10.1038/ni0703-641 · Cited by 76
Self-citationRegulated Production and Anti-HIV Type 1 Activities of Cytidine Deaminases APOBEC3B, 3F, and 3G
Rose, K. M., Marin, M., Kozak, S. L., & Kabat, D. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.611 · Cited by 60
Cited by
Harris, R. S., & Dudley, J. P. (2015) · Virology · doi:10.1016/j.virol.2015.03.012 · Cited by 551
HIV-1 Accessory Proteins—Ensuring Viral Survival in a Hostile Environment
Malim, M. H., & Emerman, M. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.04.008 · Cited by 551
Self-citationHu, W.-S., & Hughes, S. H. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006882 · Cited by 505
HIV Restriction Factors and Mechanisms of Evasion
Malim, M. H., & Bieniasz, P. D. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006940 · Cited by 487
Self-citationChiu, Y.-L., & Greene, W. C. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090350 · Cited by 416
Metadata
- Authors
- Holmes, R. K., Koning, F. A., Bishop, K. N., & Malim, M. H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 282
- Issue
- 4
- Pages
- 2587-2595
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2033631070
- Cited by
- 308
- References
- 57
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.